In his statement regarding report released by Senators Grassley and Wyden, BIO Senior VP of Communications Kenneth Lisaius stated that BIO is reviewing said report in full and generally does not comment on product pricing by member companies. Lisaius added, however, that "balanced debate about the cost of groundbreaking cures" cannot narrow their focus on price but also acknowledge value provided to patients as well as overall healthcare system.